Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase

被引：23

作者：

Davis J.M. ^{[1
,9
]}

Richter S.E. ^{[1
]}

Biswas S. ^{[1
]}

Rosenfeld W.N. ^{[1
]}

Parton L. ^{[2
]}

Gewolb I.H. ^{[3
]}

Parad R. ^{[4
]}

Carlo W. ^{[5
]}

Couser R.J. ^{[6
]}

Baumgart S. ^{[7
]}

Atluru V. ^{[1
]}

Salerno L. ^{[8
]}

Kassem N. ^{[8
]}

机构：

[1] Department of Pediatrics, Winthrop University Hospital, Mineola, NY

[2] University Hospital, Stony Brook, NY

[3] University of Maryland, Medical Center, Baltimore, MD

[4] Brigham and Women's Hospital, Boston, MA

[5] University of Alabama, Medical Center, Birmingham, AL

[6] Children's Healthcare, Minneapolis, MN

[7] Thomas Jefferson University, Philadelphia, PA

[8] Bio-Technology General Corporation, Iselin, NJ

[9] Department of Pediatrics, Winthrop University Hospital, Mineola, NY 11501

来源：

Journal of Perinatology | 2000年 / 20卷 / 4期

关键词：

D O I：

10.1038/sj.jp.7200363

中图分类号：

学科分类号：

摘要：

OBJECTIVE: To examine the long-term effects of treatment with recombinant human CuZn superoxide dismutase (rhSOD) in infants enrolled previously in two placebo-controlled trials. STUDY DESIGN: Records for 46 (88%) infants were examined, with 19 infants having received either single or multiple intratracheal (i.t.) doses of placebo, 12 having received a single i.t. dose of rhSOD, and 15 having received multiple i.t. doses of rhSOD. Mean age at follow-up was 28 months corrected age. Records were examined for neurologic dysfunction, developmental delay, and any significant medical disorders. RESULTS: Four placebo infants (21%) had evidence of neurodevelopmental abnormalities and four infants developed asthma. Four single-dose rhSOD infants (33%) had neurodevelopmental abnormalities and two infants developed asthma. One multiple-dose rhSOD infant had evidence of neurodevelopmental abnormalities and one developed asthma. No other differences were found between the placebo and rhSOD groups. CONCLUSION: Preliminary data suggest that rhSOD is safe and not associated with any long-term adverse effects. Further results will depend on the results of multicenter trials of rhSOD in preterm infants.

引用

页码：213 / 216

页数：3

共 17 条

[11]

Saugstad O.D., Oxygen radical disease in neonatology, Semin Neonatol, 3, pp. 231-238, (1998)

[12]

Rosenfeld W.N., Davis J.M., Prevention of oxygen radical disease in the newborn: Possible therapeutic approaches, Semin Neonatal, 3, pp. 239-244, (1998)

[13]

Keszler M., Modanlou H.D., Brudno D.S., Et al., Multicenter, controlled clinical trial of high-frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome, Pediatrics, 100, pp. 593-599, (1997)

[14]

Yeh T.F., Lin Y.J., Huang C.C., Et al., Early dexamethasone therapy in preterm infants: A follow-up study, Pediatrics, 101, (1998)

[15]

Pourcyrous M., Leffler C.W., Mirro R., Busija D.W., Brain superoxide anion generation during asphyxia and reventilation in newborn pigs, Pediatr Res, 28, pp. 618-621, (1990)

[16]

Kirsch J.R., Helfaer M.A., Haun S.E., Koehler R.C., Traystman R.J., Polyethylene glycolconjugated superoxide dismutase improves recovery of postischemic hypercapnic cerebral blood flow in piglets, Pediatr Res, 34, pp. 530-537, (1993)

[17]

Davis J.M., Rosenfeld W.W., Richter S.E., Et al., The effects of multiple doses of recombinant human superoxide dismutase in premature infants with respiratory distress syndrome, Pediatr Res, 45, (1999)

← 1 2 →